Search hospitals > California > Stanford
Stanford Health Care
Claim this profileStanford, California 94305
Conducts research for Pulmonary Arterial Hypertension
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Acute Myelogenous Leukemia
Conducts research for Acute Myeloid Leukemia
Conducts research for Myelodysplastic Syndrome
63 reported clinical trials
8 medical researchers
Summary
Stanford Health Care is a medical facility located in Stanford, California. This center is recognized for care of Pulmonary Arterial Hypertension, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome and other specialties. Stanford Health Care is involved with conducting 63 clinical trials across 161 conditions. There are 8 research doctors associated with this hospital, such as Robert Lowsky, MD, Everett Meyer, MD, Sally Arai, MD, and Andrew Rezvani, MD.Area of expertise
1Pulmonary Arterial Hypertension
2Acute Lymphoblastic Leukemia
HLA-A positive
HLA-A negative
HLA positive
Top PIs
Robert Lowsky, MDStanford University2 years of reported clinical research
Studies Immune Tolerance
Studies Non-Hodgkin's Lymphoma
14 reported clinical trials
22 drugs studied
Everett Meyer, MDStanford University2 years of reported clinical research
Studies Leukemia
Studies Myelodysplastic Syndrome
12 reported clinical trials
23 drugs studied
Sally Arai, MDStanford University4 years of reported clinical research
Studies Myelodysplastic Syndrome
Studies Acute Myelogenous Leukemia
8 reported clinical trials
23 drugs studied
Andrew Rezvani, MDStanford University2 years of reported clinical research
Studies Non-Hodgkin's Lymphoma
Studies Leukemia
7 reported clinical trials
12 drugs studied
Clinical Trials running at Stanford Health Care
Cardiovascular Disease
Pulmonary Arterial Hypertension
Cancer
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Liver Cancer
Heart Disease
Coronary Artery Disease
Coronary Dilatation Catheter
for Heart Disease
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation of Chronic Total Occlusion (CTO) lesions during percutaneous coronary intervention. One hundred seventy (170) subjects will be enrolled with a target of one hundred fifty-three (153) evaluable subjects by the angiographic core laboratory at up to 15 clinical sites with the Sapphire 3 0.85, 1.0 and 1.25mm diameter PTCA dilatation catheter to pre-dilate CTO lesions in coronary arteries during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through study completion, which is defined as 24-hours post-procedure or hospital discharge, whichever comes first.
Recruiting1 award N/A5 criteria
Tendyne Transcatheter Mitral Valve System
for Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Recruiting1 award N/A4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Stanford Health Care?
Stanford Health Care is a medical facility located in Stanford, California. This center is recognized for care of Pulmonary Arterial Hypertension, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome and other specialties. Stanford Health Care is involved with conducting 63 clinical trials across 161 conditions. There are 8 research doctors associated with this hospital, such as Robert Lowsky, MD, Everett Meyer, MD, Sally Arai, MD, and Andrew Rezvani, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.